Baird Financial Group’s Enzo Biochem, Inc. ENZ Stock Holding History

Baird Financial Group’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15,000	Closed	-$36.5K	–	1771
2023 Q1	$36.5K	Hold	15,000	–	–	﹤0.01%	1672
2022 Q4	$21K	Hold	15,000	–	–	﹤0.01%	1674
2022 Q3	$33K	Hold	15,000	–	–	﹤0.01%	1687
2022 Q2	$31K	Hold	15,000	–	–	﹤0.01%	1759
2022 Q1	$44K	Hold	15,000	–	–	﹤0.01%	1787
2021 Q4	$48K	Hold	15,000	–	–	﹤0.01%	1863
2021 Q3	$53K	Hold	15,000	–	–	﹤0.01%	1845
2021 Q2	$48K	Hold	15,000	–	–	﹤0.01%	1731
2021 Q1	$52K	Hold	15,000	–	–	﹤0.01%	1676
2020 Q4	$38K	Hold	15,000	–	–	﹤0.01%	1559
2020 Q3	$32K	Hold	15,000	–	–	﹤0.01%	1478
2020 Q2	$34K	Hold	15,000	–	–	﹤0.01%	1498
2020 Q1	$38K	Buy	+15,000	New	+$36.8K	﹤0.01%	1403

Other funds holding ENZ

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

RAM

Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baird Financial Group's ENZ Position: Q2 2023 in Review

Baird Financial Group sold out of Enzo Biochem, Inc. (ENZ) in Q2 2023, closing a stake of 15,000 shares — an estimated $36.5K sold.

Baird Financial Group first reported a position in ENZ in Q1 2020 and held it in 13 quarters. The position peaked at $53K in Q3 2021. 47 funds tracked by Wall St. Rank hold ENZ as of Q2 2023.

Baird Financial Group reported no remaining Enzo Biochem, Inc. position as of Q2 2023 after selling out during the quarter.
Baird Financial Group sold 15,000 Enzo Biochem, Inc. shares in Q2 2023, an estimated $36.5K.
Baird Financial Group first reported a position in Enzo Biochem, Inc. in Q1 2020 and held it in 13 quarters.
Baird Financial Group's Enzo Biochem, Inc. position peaked at $53K in Q3 2021.
47 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2023.

Based on Baird Financial Group's 13F filing for Q2 2023, filed 11 Aug 2023.